Trial · NCT00324675

Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy

NCT00324675, Not applicable, Completed, Technische Universität Dresden; results first posted 2011-10-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy. Trials, record NCT00324675. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00324675

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
NCT number: NCT00324675
Status: Completed
Phases: Not applicable
Enrollment: 28 participants, actual
Lead sponsor: Technische Universität Dresden
Conditions: Type 2 Diabetes, Overt Diabetic Nephropathy
Interventions: Rosiglitazone, Placebo
First posted: 2006-05-11
Last updated: 2011-11-02
Results first posted: 2011-10-21

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Proteinuria	at baseline and after 6 and 12 mo of treatment
Secondary	Renal Hemodynamic	at baseline and after 6 and 12 mo of tretament
Secondary	Renal Function	at abseline and after 6 and 12 mo
Secondary	Adverse Event	every month or at occurence
Secondary	HbA1c	at baseline and after 6 and 12 mo

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Proteinuria	at baseline and after 6 and 12 mo of treatment	per protocol	g/24hr	MEAN
SECONDARY	Renal Hemodynamic	at baseline and after 6 and 12 mo of tretament
SECONDARY	Renal Function	at abseline and after 6 and 12 mo
SECONDARY	Adverse Event	every month or at occurence
SECONDARY	HbA1c	at baseline and after 6 and 12 mo

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Proteinuria	Rosiglitazone	baseline	2.4	Standard Error 1.1	g/24hr
Proteinuria	Placebo	baseline	1.6	Standard Error 0.6	g/24hr
Proteinuria	Rosiglitazone	6 mo	1.2	Standard Error 0.6	g/24hr
Proteinuria	Placebo	6 mo	1.6	Standard Error 0.8	g/24hr
Proteinuria	Rosiglitazone	12 mo	1.5	Standard Error 0.7	g/24hr
Proteinuria	Placebo	12 mo	1.7	Standard Error 0.8	g/24hr

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Rosiglitazone	14
Overall Study	STARTED	Placebo	14
Overall Study	COMPLETED	Rosiglitazone	13
Overall Study	COMPLETED	Placebo	14
Overall Study	NOT COMPLETED	Rosiglitazone	1
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events18

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	peripheral edema	Skin and subcutaneous tissue disorders	Rosiglitazone	8	14	8
other	peripheral edema	Skin and subcutaneous tissue disorders	Placebo	3	14	3
other	anemia new or worsening	Blood and lymphatic system disorders	Rosiglitazone	4	14	4
other	anemia new or worsening	Blood and lymphatic system disorders	Placebo	4	14	4
other	hypoglycemia	Endocrine disorders	Rosiglitazone	2	14	2
other	hypoglycemia	Endocrine disorders	Placebo	0	14	0
other	painful calf or foot	Musculoskeletal and connective tissue disorders	Rosiglitazone	3	14	3
other	painful calf or foot	Musculoskeletal and connective tissue disorders	Placebo	1	14	1
other	hypotension	Vascular disorders	Rosiglitazone	2	14	2
other	hypotension	Vascular disorders	Placebo	0	14	0

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Rosiglitazone
Total, all-cause mortality	Placebo
Total, other adverse events	Rosiglitazone	12	14
Total, other adverse events	Placebo	9	14
Total, serious adverse events	Rosiglitazone	1	14
Total, serious adverse events	Placebo	2	14

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22723267	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Rosiglitazone vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00324675

GET https://conductscience.org/api/trials/v1/NCT00324675/registered

API reference For AI assistants